EGFR and non-small cell lung carcinoma: Based on the KN-189 trial [6], pembrolizumab in combination with chemotherapy (combination therapy) is superior to chemotherapy monotherapy in patients with non-squamous NSCLC unselected by PD-L1 staining, and no sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations.